PRIMAL METABOLICS

Iron Sharpens Iron

Proverbs 27:17

100% products made, company owned and operated in the USA

Tested for identity, purity, and/or concentration

Every batch of peptides is blended by our USA based 503a & 503b compounding pharmacy

Proprietary Blends

&

single peptides

Constituted and ready to use

no powders, no guessing, no mixing. Every vial ships fully compounded and verified for stability.

View

Revolutionary peptide formulas

Third-party verification for potency, sterility, and purity.

COAs available for every order — full transparency, zero guesswork.

Built entirely around licensed medical supervision and legally structured oversight for 503A and 503B facilities.

View

Discover what you've been missing. Shop now and elevate your standards!

Disclaimer

The statements made within this website have not been evaluated by the US Food and Drug Administration. The products offered by PrimalMetabolics.com are not intended to diagnose, treat, cure, or prevent any disease.

ALL PRODUCTS ARE SOLD FOR IN-VITRO RESEARCH AND LABORATORY DEVELOPMENT USE ONLY. THEY ARE NOT FOR HUMAN CONSUMPTION OR DIAGNOSTIC USE.

The customer acknowledges the risks associated with handling these products and certifies that they have the proper equipment, facilities, and trained personnel to manage those risks. The customer knowingly accepts these risks and agrees to indemnify and hold PrimalMetabolics.com harmless from any claims arising from the misuse or misapplication of these products outside of their intended, stated purpose.

References and Clinical Data

GHK-Cu Pickart, L. et al. (2009). The Human Tripeptide GHK and Tissue Remodeling. Journal of Biomaterials Science. US National Library of Medicine. PubChem CID: 16218791 CJC-1295 Teichman SL et al. (2006). Pharmacokinetics of CJC-1295, a long-acting growth hormone-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(4): 799–805. Ipamorelin Svensson J et al. (2000). Ipamorelin, a new growth hormone-releasing peptide. European Journal of Endocrinology, 143(6): 667–675. BPC-157 Sikiric, P. et al. (2018). Stable Gastric Pentadecapeptide BPC-157: An Overview of the Healing Effect.Current Pharmaceutical Design. PubChem CID: 9941957 TB-500 (Thymosin Beta-4 fragment) Goldstein, A.L. et al. (2005). Thymosin Beta 4 and Tissue Repair. Annals of the New York Academy of Sciences. KPV (α-MSH tripeptide fragment) Getting, S.J. et al. (2003). Anti-inflammatory properties of melanocortin peptides. European Journal of Pharmacology. LL-37 Doss, M. et al. (2010). LL-37, the Only Human Member of the Cathelicidin Family of Antimicrobial Peptides.Biochimica et Biophysica Acta. Thymosin Alpha-1 (TA1) Garaci E et al. (2007). Thymosin alpha-1 in the treatment of cancer, infections and autoimmune diseases.International Journal of Immunopharmacology. DSIP (Delta Sleep-Inducing Peptide) Graf, M.V. et al. (2002). Delta-sleep-inducing peptide (DSIP) and sleep regulation. Neuropsychobiology, 45(1): 1–4. Selank Andreeva, L. et al. (2010). Selank: a novel anxiolytic peptide with nootropic properties. Neuroscience and Behavioral Physiology. Oxytocin Carter, C.S. (2014). Oxytocin pathways and the evolution of human behavior. Annual Review of Psychology. Tesamorelin Falutz J. et al. (2010). Tesamorelin Treatment Reduces Visceral Fat and Improves Metabolic Parameters. Journal of Clinical Endocrinology & Metabolism, 95(9): 4291–4301. MOTS-c Lee, C. et al. (2015). MOTS-c: A Mitochondrial-Derived Peptide that Regulates Energy Metabolism. Cell Metabolism. AOD-9604 Ng, F.M. et al. (2000). AOD9604, a growth hormone fragment, stimulates lipolysis and inhibits lipogenesis. Obesity Research.

Account

Your cart is empty